News Story: Full Text
Sponsored By
AbbVie
Please Click On The Above Banner For More Details
Braintumor Website


Safety and feasibility of long-term temozolomide treatment in patients with high-grade glioma


Al Musella's Comments: (This is his personal views and are not necessarily the views of the Musella Foundation!)



Website: http://www.neurology.org/cgi/content/abstract/68/9/688

Posted on: 07/03/2007

NEUROLOGY 2007;68:688-690
© 2007
American Academy of Neurology

Safety and feasibility of long-term temozolomide treatment in patients with high-grade glioma

P. Hau, MD, D. Koch, MD, T. Hundsberger, MD, E. Marg, MD, B. Bauer, MD, R. Rudolph, MD, M. Rauch, MD, A. Brenner, MD, P. Rieckmann, MD, J. Schuth, MD, T. Jauch, RN, H. Koch, MD, PhD and U. Bogdahn, MD

From the Klinik und Poliklinik für Neurologie der Universität Regensburg im Bezirksklinikum (P.H., T.J., H.K., U.B.), Universitätsstraße 84, Klinik und Poliklinik für Neurochirurgie (D.K.), Universität Mainz, Langenbeckstrasse 1, Klinik und Poliklinik für Neurologie (T.H.), Universität Mainz, Langenbeckstrasse 1, Landesklinik Brandenburg (E.M.), Klinik für Neurologie, Anton-Saekow-Allee, Klinikum Neubrandenburg (B.B.), Abteilung für Neurologie, Salvadore-Allende-Strasse 30, Facharztpraxis für Internistische Onkologie (R.R.), Kettwiger Strasse 64, Essen, Krankenanstalten Gilead (M.R.), Abteilung für Neurologie, Burgsteig 13, Bielefeld, Werner-Forßmann-Krankenhaus (A.B.), Abteilung für Neurochirurgie, Rudolf-Breitscheid-Strasse 100, Eberswalde, Klinikum der Universität Würzburg (P.R.), Klinik für Neurologie, Josef-Schneider-Strasse 11, Würzburg, Germany, and essex pharma GmbH (J.S.), Thomas-Dehler-Straße 27, München, Germany.

Address correspondence and reprint requests to Dr. P. Hau, Department of Neurology, District Medical Center, University of Regensburg, Universitätsstraße 84, 93053 Regensburg, Germany; e-mail: peter.hau@medbo.de

We surveyed neuro-oncologists regarding patients treated with temozolomide for at least 12 cycles or 12 months. Patients receiving first-line temozolomide for a median 13 cycles had a median progression-free survival (PFS) of 14 months. Patients with recurrent disease receiving a median 14 cycles had a median PFS of 15.5 months. A small percentage of patients experienced grade III to IV toxicity. These results suggest that long-term treatment with temozolomide is feasible and well tolerated.

 





Click HERE to return to brain tumor news headlines


Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2019 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740